What Is Definium Therapeutics, Inc. (DFTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Definium Therapeutics, Inc.'s intrinsic value is estimated at $19.98. Trading at its current price of $45.66, the valuation engine raises significant caution: 8 of 10 models flag downside risk, projecting an average implied return of -56.3%. Notably, Sentiment SOTP sees the most upside at +29.3% (fair value: $59.04), while ML-RIV is the most conservative at -98.9% ($0.49). The spread between these extremes — +128.2% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About DFTX?
10 of 13 models are currently active for DFTX. Of these, 2 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates DFTX's intrinsic value at $14.68, implying -67.8% downside from the current price. See which stocks rank higher →
How Does DFTX Rank in Medicinal Chemicals & Botanical Products?
Among 17 Medicinal Chemicals & Botanical Products stocks, DFTX ranks #15 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.
The Medicinal Chemicals & Botanical Products sector introduces analytical considerations specific to manufacturing company businesses. For Definium Therapeutics, Inc., metrics like margin expansion trajectory provide important context that general-purpose valuation models may underweight.
Is DFTX a Value Trap?
CirclFi's Value Trap algorithm assigns DFTX a score of 31/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Definium Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Definium Therapeutics, Inc. scores 4.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +128.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every DFTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across DFTX's 10 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad